Advertisement
ARRY vs TECH
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARRY is a Buy and TECH is a Hold.
ARRY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ARRY turned positive on October 27, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ARRY as a result. In 71 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
ARRY moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +40.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 191 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
ARRY broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.039) is normal, around the industry mean (2.524). P/E Ratio (-5.521) is within average values for comparable stocks, (5.820). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. ARRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Momentum Indicator for TECH turns positive, indicating new upward trend
TECH saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 59 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TECH advanced for three days, in 190 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 94 of 231 cases where TECH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 41%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 60 cases where TECH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TECH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
TECH broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. TECH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.405) is normal, around the industry mean (2.788). P/E Ratio (62.103) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (2.110) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (133.911) among similar stocks. P/S Ratio (9.346) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TECH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARRY | TECH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 74 | |
PRICE GROWTH RATING 1..100 | 47 | 27 | |
P/E GROWTH RATING 1..100 | 32 | 89 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRY's Valuation (10) in the Biotechnology industry is significantly better than the same rating for TECH (93). This means that ARRY’s stock grew significantly faster than TECH’s over the last 12 months.
ARRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as TECH (100). This means that ARRY’s stock grew similarly to TECH’s over the last 12 months.
TECH's SMR Rating (74) in the Biotechnology industry is in the same range as ARRY (100). This means that TECH’s stock grew similarly to ARRY’s over the last 12 months.
TECH's Price Growth Rating (27) in the Biotechnology industry is in the same range as ARRY (47). This means that TECH’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's P/E Growth Rating (32) in the Biotechnology industry is somewhat better than the same rating for TECH (89). This means that ARRY’s stock grew somewhat faster than TECH’s over the last 12 months.
| ARRY | TECH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 65% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 83% | N/A |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 55% |
| Advances ODDS (%) | 3 days ago 76% | 9 days ago 66% |
| Declines ODDS (%) | 12 days ago 89% | 15 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 41% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRY’s FA Score shows that 2 FA rating(s) are green while TECH’s FA Score has 1 green FA rating(s).
- ARRY’s FA Score: 2 green, 3 red.
- TECH’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 4 TA indicator(s) are bullish while TECH’s TA Score has 3 bullish TA indicator(s).
- ARRY’s TA Score: 4 bullish, 5 bearish.
- TECH’s TA Score: 3 bullish, 3 bearish.
Price Growth
ARRY (@Alternative Power Generation) experienced а +48.88% price change this week, while TECH (@Biotechnology) price change was -0.07% for the same time period.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was +8.88%. For the same industry, the average monthly price growth was -5.89%, and the average quarterly price growth was -41.40%.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.09%. For the same industry, the average monthly price growth was -4.28%, and the average quarterly price growth was -15.49%.
Reported Earning Dates
ARRY is expected to report earnings on Mar 03, 2027.
TECH is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Alternative Power Generation (+8.88% weekly)The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
@Biotechnology (+7.09% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARRY and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARRY has been closely correlated with NXT. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARRY jumps, then NXT could also see price increases.
| Ticker / NAME | Correlation To ARRY | 1D Price Change % | ||
|---|---|---|---|---|
| ARRY | 100% | -0.56% | ||
| NXT - ARRY | 67% Closely correlated | -6.67% | ||
| SHLS - ARRY | 61% Loosely correlated | -1.80% | ||
| AXON - ARRY | 53% Loosely correlated | -9.81% | ||
| INO - ARRY | 52% Loosely correlated | -10.49% | ||
| ENPH - ARRY | 51% Loosely correlated | -8.18% | ||
More | ||||